The month of November was off to an exciting start as our first public stock offering was qualified by the SEC and our first crowdfunding campaign under Regulation A was launched.
Regulation A offering to the general public allows an opportunity to anyone, not just accredited investors and institutions, to invest in DNALabs at an early stage and at the same time to provide us the opportunity to build a large number of small investors who become brand ambassadors and online promoters of the DNALabs product.
I spent a few days in Los Angeles attending the 2022 Equity Crowdfunding Week where I met a lot of very interesting people involved in crowdfunding and learned about the growth and future of the new way to raise capital.
We are building a company together with our investors and are focused on innovation and a better future for everyone. Every dollar that we raise helps us build our company with the goal to grow quickly – but responsibly and will help us scale and help our goal to become a leader in the global genetic testing market, a market that is expected to reach US$ 23.1 billion by 2027.
We have a strong scientific team continuously expanding and improving our product offering, and partnerships with world class hospitals and academic institutions working together with us to find a better future for everyone.
Chief Executive Officer